Excellent long-term survival after allogeneic marrow transplantation in patients with severe aplastic anemia

Bone Marrow Transplantation

Volumn 19, Issue 12, 1997, Pages 1191-1196

  Reiter, E ^a   Keil, F ^a   Brugger, S ^a   Kalhs, P ^a   Rabitsch, W ^a   Hinterberger, W ^b   Fischer, G ^b   Rosenmayr, A ^b   Haas, O ^c   Volc, B ^b   Lechner, K ^a   Greinix, H T ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c ST ANNA CHILDREN S HOSPITAL   (Austria)

Author keywords

Allogeneic marrow transplantation; Aplastic anemia; Long term follow up

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; METHOTREXATE; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; CLINICAL ARTICLE; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; MALE; MONOZYGOTIC TWINS; MORBIDITY; ORGAN DONOR; PRIORITY JOURNAL; SIBLING; SURVIVAL; THROMBOCYTE TRANSFUSION; TIME; TREATMENT PLANNING; WHOLE BODY RADIATION;

EID: 0030861092     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700819     Document Type: Article

References (20)

1. Young NS, Barrett AJ. The treatment of severe acquired aplastic anemia. Blood 1995; 85: 3367-3377.
2. Storb R, Etzioni R, Anasetti C et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood 1994; 84: 941-949.
3. Bacigalupo A, Hows J, Gluckman E et al. Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anemia (SAA): a report of the EBMT SAA working party. Br J Haematol 1988; 70: 177-182.
4. Gluckman E, Horowitz MM, Champlin RE et al. Bone marrow transplantation for severe aplastic anemia: influence of conditioning and graft-versus-host disease prophylaxis regimens on outcome. Blood 1992; 79: 269-275.
5. Kernan NA, Bartsch G, Ash RC et al. Analysis of 462 transplantations from unrelated donors facilitated by The National Marrow Donor Program. New Engl J Med 1993; 328: 593-602.
6. May WS, Sensenbrenner LL, Burns WH et al. BMT for severe aplastic anemia using cyclosporine. Bone Marrow Transplant 1993; 11: 459-464.
7. Champlin RE, Horowitz MM, van Bekkum DW et al. Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood 1989; 73: 606-613.
8. Storb R, Doney KC, Thomas ED et al. Marrow transplantation with or without donor buffy coat cells for 65 transfused aplastic anemia patients. Blood 1982; 59: 236-246.
9. Gale RP, Bortin MM, van Bekkum DW et al. Risk factors for acute graft-versus-host disease. Br J Haematol 1987; 67: 397-406.
10. Storb R, Deeg HJ, Farewell K et al. Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood 1986; 68: 119-125.
11. Camilla BM, Thomas ED, Nathan DG et al. A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. Blood 1979; 53: 504-514.
12. Feig SA, Champlin R, Arenson E et al. Improved survival following bone marrow transplantation for aplastic anaemia. Br J Haematol 1983; 54: 509-517.
13. Thomas ED, Storb R, Clift RA et al. Bone marrow transplantation. New Engl J Med 1975; 292: 832-843, 895-902.
14. Sullivan KM, Shulman HM, Storb R et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57: 267-276.
15. Gaiger A, Mannhalter C, Hinterberger W et al. Detection of engraftment and mixed chimerism following bone marrow transplantation using PCR amplification of a highly variable region-variable number of tandem repeats (VNTR) in the von Willebrand factor gene. Ann Hematol 1991; 63: 227-228.
16. Socie G, Henry-Amar M, Bacigalupo A et al. Malignant tumors occuring after treatment of aplastic anemia. New Engl J Med 1993; 329: 1152-1157.
17. Sanders JE and the Seattle Marrow Transplant Team. The impact of marrow transplant preparative regimens on subsequent growth and development. Semin Hematol 1991; 28: 244-249.
18. Deeg HJ, Socie G, Schoch G et al. Malignancies after marrow transplantation for aplastic anemia and Fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood 1996; 87: 386-392.
19. Hows JM, Yin J, Marsh J et al. Histocompatible unrelated volunteer donors compared with HLA nonidentical family donors in marrow transplantation for aplastic anemia and leukemia. Blood 1986; 68: 1322-1328.
20. Deeg HJ, Anasetti C, Petersdorf E et al. Cyclophosphamide plus ATG conditioning is insufficient for sustained hematopoietic reconstitution in patients with severe aplastic anemia transplanted with marrow from HLA-A, B, DRB matched unrelated donors. Blood 1994; 11: 3417-3421.